UK Suspends Amgen Drug Tavneos
Britain suspends sales of Amgens rare disease drug Tavneos to new patients due to unreliable trial data. The regulator plans to fully revoke approval next March.
Xurve View
Insights:
Xurve View
AMGEN INC suspended the sale of its rare-disease drug Tavneos to new patients in the United Kingdom on Tuesday morning after regulators flagged unreliable trial data. The British decision mirrors regulatory setbacks in Europe and the United States over the autoimmune treatment. The loss of market access threatens revenue streams from a drug acquired through a $3.7B buyout.
